This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Zytiga

Johnson & Johnson

Drug Names(s): CB7630, JNJ-212082, abiraterone acetate

Description: CB7630 is an orally active inhibitor of the steroidal enzyme 17 alpha-hydroxylase/C17,20 lyase, a cytochrome p450 complex that is involved in testosterone production. In preclinical studies, CB7630 has demonstrated the ability to selectively inhibit the target enzyme, resulting in inhibition of testosterone production in both the adrenals and the testes.

Deal Structure: Revenue splits for this drug are BioMedTracker estimates.

Cougar and BTG
In April 2004, Cougar exclusively licensed the worldwide rights to CB7630 (abiraterone acetate) from BTG. Cougar paid BTG an initial license fee of $923,100 and agreed to pay BTG an annual license maintenance fee of GBP 150,000 until the first commercial sale of the licensed product. Cougar is required to make aggregate milestone payments of up to GBP 9,000,000 payable upon the achievement of clinical and regulatory milestones and will be obligated to pay BTG an annual royalty based on net sales of the drug.

Johnson & Johnson and Cougar
In May 2009, Johnson & Johnson and Cougar Biotechnology announced a definitive agreement whereby Cougar Biotechnology will be acquired for approximately $1.0 billion in a cash tender offer. Under the terms of the agreement, Johnson & Johnson will initiate a tender offer, through a new wholly-owned subsidiary, to purchase all outstanding shares of...See full deal structure in Biomedtracker

Partners: BTG plc AstraZeneca PLC


Zytiga News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug